# Cagrilintide

> Long-acting amylin analog studied alongside GLP-1 agonists.

Source: https://peptides.cafe/peptide/cagrilintide
Category: Metabolic · Amylin
Tag: Weight loss

## Mechanism
A long-acting analog of amylin, a pancreatic hormone co-secreted with insulin. It slows gastric emptying, increases satiety, and suppresses glucagon — complementary to GLP-1 mechanisms.

## Research areas
- Weight management as monotherapy and combined with semaglutide (CagriSema)
- Glycemic control in type 2 diabetes

## Common research protocols
- Weekly subcutaneous clinical research: Investigational weekly dosing, often paired with semaglutide in trials.

## Study summaries
- "Cagrilintide plus semaglutide for obesity (Phase 2)" — The Lancet (2021): Combination produced greater weight loss than either agent alone.

## Considerations
- Investigational; not yet FDA-approved as monotherapy.
- GI side effects similar to GLP-1 agonists.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.